Skip to main content
Erschienen in: Urolithiasis 3/2011

01.06.2011 | Original Paper

Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats

verfasst von: P. Vanachayangkul, N. Chow, S. R. Khan, Veronika Butterweck

Erschienen in: Urolithiasis | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

In Egypt, teas prepared from the fruits of Ammi visnaga L. (syn. “Khella”) are traditionally used by patients with urolithiasis. The aim of this study was to evaluate whether oral administration of an aqueous extract prepared from the fruits of A. visnaga as well as two major constituents khellin and visnagin could prevent crystal deposition in stone-forming rats. Hyperoxaluria was induced in male Sprague-Dawley rats by giving 0.75% ethylene glycol and 1% ammonium chloride via the drinking water. The Khella extract (KE; 125, 250 or 500 mg/kg) was orally administered for 14 days. The histopathological examination of the kidneys revealed that KE significantly reduced the incidence of calcium oxalate (CaOx) crystal deposition. In addition, KE significantly increased urinary excretion of citrate along with a decrease of oxalate excretion. Comparable to the extract, khellin and visnagin significantly reduced the incidence of CaOx deposition in the kidneys. However, both compounds did not affect urinary citrate or oxalate excretion indicating a mechanism of action that differs from that of the extract. For KE, a reasonably good correlation was observed between the incidence of crystal deposition, the increase in citrate excretion and urine pH suggesting a mechanisms that may interfere with citrate reabsorption. In conclusion, our data suggest that KE and its compounds, khellin and visnagin, may be beneficial in the management of kidney stone disease caused by hyperoxaluria but that it is likely that different mechanism of action are involved in mediating these effects.
Literatur
1.
Zurück zum Zitat Atmani F, Slimani Y, Mimouni M, Hacht B (2003) Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats. BJU Int 92:137–140PubMedCrossRef Atmani F, Slimani Y, Mimouni M, Hacht B (2003) Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats. BJU Int 92:137–140PubMedCrossRef
2.
Zurück zum Zitat Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med 75:1095–1103PubMedCrossRef Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med 75:1095–1103PubMedCrossRef
3.
Zurück zum Zitat Chow K, Dixon J, Gilpin S, Kavanagh JP, Rao PN (2004) Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int 65:1724–1730PubMedCrossRef Chow K, Dixon J, Gilpin S, Kavanagh JP, Rao PN (2004) Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int 65:1724–1730PubMedCrossRef
4.
Zurück zum Zitat Colussi G, De Ferrari ME, Brunati C, Civati G (2000) Medical prevention and treatment of urinary stones. J Nephrol 13:S65–S70PubMed Colussi G, De Ferrari ME, Brunati C, Civati G (2000) Medical prevention and treatment of urinary stones. J Nephrol 13:S65–S70PubMed
5.
Zurück zum Zitat Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273–3277PubMedCrossRef Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273–3277PubMedCrossRef
6.
Zurück zum Zitat Gerstenbluth RE, Resnick MI (2004) Medical management of calcium oxalate urolithiasis. Med Clin North Am 88:431–442PubMedCrossRef Gerstenbluth RE, Resnick MI (2004) Medical management of calcium oxalate urolithiasis. Med Clin North Am 88:431–442PubMedCrossRef
7.
Zurück zum Zitat Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG (1989) Urine citrate and renal stone disease. Can Med Assoc J 141:217–221 Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG (1989) Urine citrate and renal stone disease. Can Med Assoc J 141:217–221
8.
Zurück zum Zitat Gunaydin K, Beyazit N (2004) The chemical investigations on the ripe fruits of Ammi visnaga (LAM.) Lamarck growing in Turkey. Nat Prod Res 18:169–175PubMedCrossRef Gunaydin K, Beyazit N (2004) The chemical investigations on the ripe fruits of Ammi visnaga (LAM.) Lamarck growing in Turkey. Nat Prod Res 18:169–175PubMedCrossRef
9.
Zurück zum Zitat Huang HS, Ma MC, Chen J, Chen CF (2002) Changes in the oxidant–antioxidant balance in the kidney of rats with nephrolithiasis induced by ethylene glycol. J Urol 167:2584–2593PubMedCrossRef Huang HS, Ma MC, Chen J, Chen CF (2002) Changes in the oxidant–antioxidant balance in the kidney of rats with nephrolithiasis induced by ethylene glycol. J Urol 167:2584–2593PubMedCrossRef
10.
Zurück zum Zitat Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15:236–243PubMedCrossRef Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15:236–243PubMedCrossRef
11.
Zurück zum Zitat Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349–357PubMedCrossRef Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349–357PubMedCrossRef
12.
Zurück zum Zitat Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef
13.
Zurück zum Zitat Khan SR, Glenton PA, Byer K (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline. Kidney Int 70:914–923PubMedCrossRef Khan SR, Glenton PA, Byer K (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline. Kidney Int 70:914–923PubMedCrossRef
14.
Zurück zum Zitat Khan ZA, Assiri AM, Al-Afghani HM, Maghrabi TM (2001) Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI-Khillah). Int Urol Nephrol 33:605–608PubMedCrossRef Khan ZA, Assiri AM, Al-Afghani HM, Maghrabi TM (2001) Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI-Khillah). Int Urol Nephrol 33:605–608PubMedCrossRef
15.
16.
Zurück zum Zitat Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215:383–389PubMedCrossRef Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215:383–389PubMedCrossRef
17.
Zurück zum Zitat Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate—a critical review. Urol Res 33:73–79PubMedCrossRef Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate—a critical review. Urol Res 33:73–79PubMedCrossRef
18.
Zurück zum Zitat Modlinger PS, Welch WJ (2003) Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12:497–502PubMedCrossRef Modlinger PS, Welch WJ (2003) Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12:497–502PubMedCrossRef
19.
Zurück zum Zitat Pak CY (1987) Citrate and renal calculi. Miner Electrolyte Metab 13:257–266PubMed Pak CY (1987) Citrate and renal calculi. Miner Electrolyte Metab 13:257–266PubMed
20.
Zurück zum Zitat Pak CY (1991) Etiology and treatment of urolithiasis. Am J Kidney Dis 18:624–637PubMed Pak CY (1991) Etiology and treatment of urolithiasis. Am J Kidney Dis 18:624–637PubMed
21.
Zurück zum Zitat Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334PubMedCrossRef Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334PubMedCrossRef
22.
Zurück zum Zitat Poulsen SA, Quinn RJ (1998) Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 6:619–641PubMedCrossRef Poulsen SA, Quinn RJ (1998) Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 6:619–641PubMedCrossRef
23.
Zurück zum Zitat HWBOaOKP Rauwald (1994) The involvement of a Ca2+ channel blocking mode of action in the pharmacology of Ammi visnaga fruits. Planta Med 60:101–105CrossRef HWBOaOKP Rauwald (1994) The involvement of a Ca2+ channel blocking mode of action in the pharmacology of Ammi visnaga fruits. Planta Med 60:101–105CrossRef
24.
Zurück zum Zitat Renata C, Fabio V, Angela B, Sergio S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci 8:S1084–S1106CrossRef Renata C, Fabio V, Angela B, Sergio S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci 8:S1084–S1106CrossRef
25.
Zurück zum Zitat Sakhaee K, Alpern R, Poindexter J, Pak CYC (1992) Citraturic response to oral citric-acid load. J Urol 147:975–976PubMed Sakhaee K, Alpern R, Poindexter J, Pak CYC (1992) Citraturic response to oral citric-acid load. J Urol 147:975–976PubMed
26.
Zurück zum Zitat Sarica K, Inal Y, Erturhan S, Yagci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34:184–189PubMedCrossRef Sarica K, Inal Y, Erturhan S, Yagci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34:184–189PubMedCrossRef
27.
Zurück zum Zitat Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758–767PubMedCrossRef Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758–767PubMedCrossRef
28.
Zurück zum Zitat Unwin RJ, Capasso G, Shirley DG (2004) An overview of divalent cation and citrate handling by the kidney. Nephron Physiol 98:15–20CrossRef Unwin RJ, Capasso G, Shirley DG (2004) An overview of divalent cation and citrate handling by the kidney. Nephron Physiol 98:15–20CrossRef
29.
Zurück zum Zitat Vanachayangkul P, Byer K, Khan S, Butterweck V (2010) An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 17:653–658PubMedCrossRef Vanachayangkul P, Byer K, Khan S, Butterweck V (2010) An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 17:653–658PubMedCrossRef
30.
Zurück zum Zitat Worcester EM, Coe FL (2008) Nephrolithiasis. Prim Care 35:369–391 (vii) Worcester EM, Coe FL (2008) Nephrolithiasis. Prim Care 35:369–391 (vii)
31.
Zurück zum Zitat Yuliana ND, Khatib A, Link-Struensee AM, Ijzerman AP, Rungkat-Zakaria F, Choi YH, Verpoorte R (2009) Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus. Planta Med 75:132–136PubMedCrossRef Yuliana ND, Khatib A, Link-Struensee AM, Ijzerman AP, Rungkat-Zakaria F, Choi YH, Verpoorte R (2009) Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus. Planta Med 75:132–136PubMedCrossRef
Metadaten
Titel
Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats
verfasst von
P. Vanachayangkul
N. Chow
S. R. Khan
Veronika Butterweck
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Urolithiasis / Ausgabe 3/2011
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-010-0333-y

Weitere Artikel der Ausgabe 3/2011

Urolithiasis 3/2011 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.